Table 1 Baseline demographic, clinical treatment and psychosocial characteristics of participants
Variable | Full cohort | With VL at week 16 | With VL at week 48 |
|---|---|---|---|
Number: n | 230 | 160 | 180 |
Female sex: n (%) | 150 (65.2) | 108 (67.5) | 121 (67.2) |
Age in years: mean (SD) | 34.5 (9.1) | 34.8 (8.9) | 35.0 (9.4) |
Height (cm): mean (SD) | 164.0 (8.6) | 164.1 (8.2) | 164.0 (8.1) |
Weight (kg): median (IQR) | 67.3 (57.8–79.6) | 67.2 (58.0–80.0) | 68.1 (58.7–80.4) |
BMI: median (IQR) | 24.3 (21.3–29.8) | 24.2 (21.5–29.9) | 24.6 (21.5–30.7) |
WHO stage: n (%) | |||
1 | 84 (36.5) | 58 (36.3) | 73 (40.6) |
2 | 47 (20.4) | 34 (21.3) | 39 (21.7) |
3 | 75 (32.6) | 54 (33.8) | 51 (28.3) |
4 | 24 (10.4) | 14 (8.8) | 17 (9.4) |
CD4 count (cells/mm3): median (IQR) | 225 (133–287) | 229 (132–288) | 233 (144–287) |
Log HIV-RNA (copies/ml): median (IQR) | 4.9 (4.4–5.4) | 4.9 (4.4–5.4) | 4.8 (4.4–5.4) |
NNRTI at start: n (%) | |||
Efavirenz | 228 (99.1) | (98) | |
Nevirapine | 2 (0.9) | 2 (1.2) | 2 (1.1) |
NRTI at starta: n (%) | |||
Tenofovir | 225 (97.8) | 159 (99.4) | 177 (98.3) |
Zidovudine | 4 (1.7) | 1 (0.6) | 3 (1.7) |
Stavudine | 1 (0.4) | – | – |
HADS depression score of 8 or above (borderline or case)b: n (%) | 74 (32.1) | 55 (34.3) | 58 (32.2) |
HADS anxiety score of 8 or above (borderline or case)b: n (%) | 89 (38.7) | 64 (40.0) | 70 (38.9) |
Non-disclosure: n (%) | 11 (4.7) | 8 (5.0) | 7 (3.9) |
CAGE score ≥ 2: n (%) | 35 (15.2) | 22 (13.8) | 25 (13.9) |